What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class II recall involving a specific prescription eye drop manufactured by Micro Labs USA Inc. This action centers on the Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, USP, presented in a 10-milliliter bottle format. This medication is prescribed to treat conditions such as elevated intraocular pressure associated with open-angle glaucoma or ocular hypertension, making it a critical part of daily health routines for many individuals. The product is marketed under the brand name Micro Labs and is designated as prescription-only (Rx), indicating that it requires a doctor’s authorization to obtain.
The specific items subject to this recall are identified by precise regulatory and manufacturing details. The National Drug Code (NDC) for the affected product is 42571-147-26. It is crucial to check the lot number on your bottle, as only units from a specific production run are impacted. The recalled lot is identified as DLHU0031. These bottles were manufactured by Micro Labs Limited in India and distributed for sale by Micro Labs USA Inc., which is located in Somerset, New Jersey, with the postal code 08873. The expiration date printed on these specific bottles is June 30, 2027, meaning they are not yet expired but are being pulled from the supply chain due to packaging defects rather than product degradation.
The scope of this recall is nationwide, affecting consumers across all 50 states in the United States. There is no specific date provided in the official record for when the product was originally sold to pharmacies or patients, only that the distribution pattern covered the entire country. The recall was officially initiated on July 22, 2026. Because this is a Class II recall, it indicates a situation where use of the product may cause temporary or medically reversible health problems, though it is not expected to cause serious adverse health consequences. However, the defect itself—specifically issues with the container cap—renders the medication potentially unusable or unsafe in terms of dosage accuracy.
If you have this medication at home, do not panic, but do take immediate time to locate your bottle and verify the details against the information above. The recall is strictly limited to the NDC 42571-147-26 and Lot # DLHU0031. Other lots of the same product manufactured by Micro Labs are not part of this specific action. It is important to distinguish between the brand name, the generic ingredients (Dorzolamide HCl 2% and Timolol Maleate 0.5%), and the specific physical bottle characteristics described here. The recall does not involve other strengths or volumes of this drug, nor does it involve bottles manufactured by other companies.
Understanding exactly what was recalled helps prevent unnecessary worry while ensuring that you take appropriate action if your medication is part of this batch. The focus remains on the integrity of the container rather than the chemical composition of the fluid inside. By confirming your lot number and NDC, you can determine whether your specific bottle is one of the affected units. If it matches the details provided, further steps regarding remedy and contact information will be necessary, as the current record does not explicitly state the final remedy offered to consumers.
The hazard, explained
When you look at the details of this recall from Micro Labs USA Inc., the issue is surprisingly mechanical rather than chemical. The product in question is a prescription eye drop combining Dorzolamide HCl and Timolol Maleate, used to lower pressure inside the eye for conditions like glaucoma. The specific defect identified by the FDA involves the physical integrity of the bottle’s cap assembly. Specifically, the "spikes" located on the underside of the cap—small plastic protrusions designed to puncture the safety seal when you first open a new bottle—are breaking off or becoming defective.
To understand why this matters, it helps to know how these ophthalmic bottles are designed. They come sealed with a tamper-evident ring that keeps the sterile solution inside until you twist the cap. The spikes are crucial for piercing that seal cleanly. When those spikes fail or break, the seal often does not puncture properly. This creates a situation where the bottle appears ready to use, but the medication cannot flow out. You might find yourself twisting the cap vigorously, shaking the bottle, and pressing on the dropper tip, only to receive nothing but air. This is what the agency describes as "undeliverable drops."
The harm here is not necessarily from a toxic chemical reaction, but from a failure of delivery that can have serious downstream consequences for eye health. For patients managing glaucoma or ocular hypertension, consistency is critical. These medications are prescribed to be taken on a strict schedule to maintain intraocular pressure at safe levels. If the bottle fails to dispense medication due to this cap defect, you may unknowingly miss doses. This isn't just an inconvenience; it is a gap in your treatment plan that allows eye pressure to rise unchecked.
High intraocular pressure can silently damage the optic nerve over time, potentially leading to permanent vision loss or blindness if left unmanaged. While the defect itself is a manufacturing flaw in the plastic component, the clinical risk stems from the interruption of therapy. Additionally, there is a secondary physical hazard mentioned in the report: broken cap spikes. If these plastic pieces do not remain attached to the cap but instead fall into the bottle or get caught in the dispensing mechanism, they could theoretically contaminate the sterile solution or cause further blockage. While rare, any foreign object in an eye drop bottle compromises the sterility required for safe ocular use.
In summary, the hazard is a dual threat: the immediate frustration of a product that does not work when needed, and the more subtle but dangerous risk of untreated eye conditions due to missed doses. The FDA’s classification of this as a Class II recall indicates that while the situation is not immediately life-threatening in the way a toxic contamination might be, it is serious enough to require prompt attention to prevent adverse health outcomes.
Who is most at risk
To understand who is truly vulnerable in this specific recall, we first need to look at the nature of the product itself. Dorzolamide HCl and Timolol Maleate Ophthalmic Solution is not an over-the-counter eye drop you might pick up for occasional redness or dry eyes. It is a prescription-only medication (Rx only) used to treat high pressure in the eye, often associated with conditions like glaucoma or ocular hypertension. Because it requires a doctor’s prescription, the people who possess this bottle are already managing a chronic health condition that affects vision and overall quality of life. This immediately places the users in a category of individuals who require consistent, reliable medical care to prevent serious, potentially permanent eye damage.
The primary group at risk in this scenario includes anyone who has been prescribed NDC 42571-147-26, specifically from Lot # DLHU0031 with an expiration date of June 30, 2027. However, the "risk" here is twofold: first, the direct physical hazard of a broken cap spike and undeliverable drops; and second, the medical consequence of interrupted treatment. The defective container issue means that even if the medication inside is still sterile and effective, the user cannot access it properly. For someone with glaucoma, missing doses can lead to a dangerous spike in intraocular pressure. Therefore, the people most at risk are those who rely on this specific medication to maintain stable eye health and prevent optic nerve damage.
Among these patients, certain demographics may face heightened challenges. Older adults, who statistically have higher rates of glaucoma, may find it particularly difficult to troubleshoot a broken bottle cap while managing other age-related physical limitations. Fumbling with a defective container can be frustrating and time-consuming, leading some individuals to delay their treatment or attempt risky workarounds that could compromise the sterility of the remaining drops. Additionally, patients who are visually impaired or have reduced dexterity due to arthritis or other conditions may struggle more significantly with the mechanical failure of the cap spikes, making this recall a practical barrier to their care, not just a safety warning.
While the hazard described is primarily a mechanical failure of the packaging rather than a chemical contamination, the ripple effects are significant. The risk extends beyond immediate discomfort to the potential for unmanaged eye pressure. This means that anyone in the United States who has filled this specific prescription recently is part of the affected distribution pattern. It is crucial to recognize that the vulnerability lies not just in the broken plastic, but in the disruption of a critical medical routine. For these patients, the "risk" is the gap in care that occurs while they wait for a replacement or a remedy, which has not yet been explicitly detailed by the FDA or Micro Labs USA Inc. at this time.
How to tell if you have the recalled item
Verifying whether your prescription bottle is part of this specific recall requires you to pause and carefully inspect the label on your Dorzolamide HCl and Timolol Maleate Ophthalmic Solution. Because Micro Labs USA Inc. distributes these products nationwide, the issue is not with the medication’s chemical effectiveness, but rather with the physical delivery mechanism—the cap. To confirm if your bottle is affected, you need to match several specific identifiers found on the packaging. Start by looking at the front and back labels for the brand name Micro Labs. This product is manufactured by Micro Labs Limited in India and distributed by Micro Labs USA Inc. in Somerset, New Jersey.
The most critical piece of information to locate is the National Drug Code (NDC) number. You must verify that your bottle carries the code NDC 42571-147-26. Alongside the NDC, check the lot number printed on the label. The recall applies exclusively to bottles with Lot # DLHU0031. If your bottle has a different lot number or NDC, it is not part of this specific safety notice regarding defective cap spikes. Additionally, verify the expiration date. This recall is limited to bottles expiring on 06/30/2027. While the expiration date alone does not confirm the defect, it helps narrow down the batch when combined with the lot and NDC numbers.
Once you have confirmed the printed identifiers, inspect the physical bottle itself. The product is contained in a 10mL bottle and is classified as Rx only, meaning it was dispensed by a pharmacy rather than purchased over-the-counter without a prescription. Look closely at the cap assembly. The hazard associated with this recall involves broken cap spikes that can prevent drops from being delivered properly. While the label tells you what to look for on paper, the physical inspection of the dropper tip and cap mechanism is where you will determine if the unit is functional or defective. If the cap appears damaged, cracked, or if the spike is missing, do not attempt to use it.
If you are unsure whether your bottle matches these exact specifications, take a photo of the label with your lot number, NDC, and expiration date clearly visible. You can then contact Micro Labs USA Inc. directly for confirmation. Since distribution was nationwide, there is no geographic location that rules out the product being in your home. However, because the manufacturer is based in Somerset, NJ, records may be more accessible there. Do not guess; the safety risk comes from the inability to deliver the correct dose due to mechanical failure, so precise identification of the lot and NDC is essential before taking any further action.
What to do — step by step
If you have been prescribed or currently possess the Dorzolamide HCl and Timolol Maleate Ophthalmic Solution manufactured by Micro Labs USA Inc., it is important to act with care but without panic. Because this specific recall involves a Class II hazard related to defective container components—specifically broken cap spikes that prevent proper dosing—the primary goal is to ensure you do not use a bottle that may deliver an incorrect amount of medication or become contaminated. The FDA has issued this alert for NDC 42571-147-26, Lot # DLHU0031, with an expiration date of 06/30/2027. While the official recall notice does not explicitly state a specific remedy such as a direct refund process or a mandatory return address for consumers, standard protocol for pharmaceutical recalls of this nature requires immediate cessation of use and professional consultation. Please follow these steps carefully to protect your health and ensure proper management of your eye care regimen. First, stop using the affected bottles immediately. Do not attempt to force drops from a bottle with a broken cap spike, as this can lead to inaccurate dosing. Timolol is a beta-blocker that affects heart rate and blood pressure, while Dorzolamide reduces intraocular pressure; getting either of these wrong due to a malfunctioning dispenser can have serious health consequences. If you notice the cap spikes are broken or the bottle feels like it will not dispense correctly, set it aside in a safe place where children or pets cannot reach it. Do not throw it in your household trash yet, as improper disposal could pose risks to others or the environment, though specific disposal instructions were not provided in the initial alert. Second, contact your eye care professional or pharmacist right away. Since this is an Rx-only medication, you need a healthcare provider to evaluate your current treatment plan. Explain that you have the recalled lot number (DLHU0031) and ask for advice on how to proceed. They may prescribe a replacement from a different manufacturer or lot to ensure there is no gap in your treatment for glaucoma or ocular hypertension. It is crucial not to simply stop taking your eye drops without medical guidance, as untreated eye pressure issues can lead to vision loss over time. Your pharmacist may also be able to help you identify if other bottles from the same distribution batch are affected and provide guidance on how to verify your specific product against the recall list. Third, reach out to Micro Labs USA Inc. for further instructions. Although the recall facts do not list a specific phone number or website for consumer returns, you should attempt to contact the manufacturer directly at their Somerset, NJ address to inquire about potential reimbursement or replacement options. Keep your receipt and the bottle packaging handy as proof of purchase. Document any issues you experienced with the broken cap spikes, including photos if possible, as this information may be helpful for the company’s quality assurance records. If you cannot reach the manufacturer, check with the pharmacy where you filled the prescription; they often have established channels to handle recall notifications and may assist in coordinating a replacement or refund through their corporate accounts with the distributor. Finally, monitor your health closely. While the hazard here is mechanical (the container) rather than chemical contamination, any eye irritation, redness, or discomfort after using the product should be reported to your doctor immediately. If you have already used some of the drops and are experiencing unusual symptoms, seek medical attention promptly. Stay informed by checking the FDA’s website periodically for updates on this recall, as remedy details such as return addresses or refund procedures may be added to the official notice in the future.Your refund, repair, or replacement options
When you encounter a product recall, the most immediate and practical question is often, "What do I get back?" or "How do I fix this?" In the case of the Micro Labs USA Inc. recall regarding Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, USP, 2%/0.5%, we must address a specific and somewhat unusual situation: the official FDA recall documentation does not currently state a specific remedy. This means there is no publicly listed instruction for a refund, a direct replacement bottle, or a repair service at this time. While this might feel like a dead end, it is important to understand why this happens and what your options are based on how these distributions work.
The reason the remedy is not stated in this specific recall notice often comes down to the nature of the defect and the supply chain. This is a Class II recall, which indicates a situation where use of the product could cause temporary or medically reversible harm to health. The hazard here is a defective container—specifically, broken cap spikes that prevent drops from being delivered. Because the drug itself (Dorzolamide HCl and Timolol Maleate) is chemically stable and not contaminated, the issue is purely mechanical. In many pharmaceutical recalls of this type, the manufacturer may choose not to offer a direct "refund" in the traditional retail sense because prescription drugs are strictly regulated items that cannot simply be returned for cash like a shirt or a toaster. Instead, the standard industry practice is often to provide a replacement product through the pharmacy or healthcare provider who dispensed it.
So, while the recall text does not give you a phone number or an email address to call for money back, your path forward likely involves working with the source of your medication. If you purchased this specific bottle from a pharmacy, that pharmacy has a direct relationship with Micro Labs USA Inc. and their distributor. They are in the best position to determine if they can issue a credit to your account or send you a new, non-defective bottle from a different lot number. This is generally the preferred route because it ensures you receive a product that meets safety standards without the legal complications of returning a prescription drug.
If you are unsure whether your specific bottle is part of this recall, remember that the affected item is NDC 42571-147-26, Lot # DLHU0031, with an expiration date of 06/30/2027. If your bottle matches these details, do not attempt to use it. Instead, contact your pharmacy immediately. Explain that you have received notice of a Class II recall for this specific lot. The pharmacist can then initiate the return process on their end and arrange for a replacement or a credit, depending on Micro Labs USA Inc.'s internal instructions which are not public but are handled directly between the manufacturer and the dispensing pharmacy.
It is also worth noting that because this is a nationwide distribution, your experience might vary slightly depending on whether you are in New Jersey (where Micro Labs USA Inc. is based) or another state. However, the core principle remains the same: the remedy is managed through the healthcare channel, not a consumer-facing website. Do not throw the bottle away immediately if you plan to return it to the pharmacy for credit, as they may need to see the lot number for their records. Keep the bottle in a safe place until you have spoken with your pharmacist or doctor.
In summary, while there is no direct "refund button" or consumer hotline listed in this recall notice, your financial and medical interests are protected through the pharmacy system. The lack of a stated remedy in the public notice does not mean you are left without recourse; it simply means the process is handled privately between the manufacturer, the distributor, and the dispensing pharmacy to ensure regulatory compliance and patient safety.
What can happen if you ignore it
When a product recall involves eye medication, the stakes are inherently higher than with many other household items because your eyes are delicate, highly sensitive organs. In this specific case involving Micro Labs USA Inc.’s Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, the primary hazard is not chemical contamination or toxicity, but rather a mechanical failure of the container itself: broken cap spikes that prevent drops from being delivered correctly. While this might initially sound like a minor inconvenience, ignoring this defect can lead to several compounding real-world consequences for your health and your treatment plan.
The most immediate consequence is the disruption of your prescribed treatment regimen. Dorzolamide HCl and Timolol Maleate are typically prescribed to lower intraocular pressure in conditions such as open-angle glaucoma or ocular hypertension. These medications require consistent, precise dosing to be effective. If you continue to use a bottle with a broken spike, you may find that no liquid comes out, or only a tiny, unpredictable amount is dispensed. This creates a false sense of security where you believe you are taking your medication, but in reality, you are receiving little to no active ingredient. For patients managing chronic eye conditions, even a short period of missed or inconsistent dosing can allow intraocular pressure to rise, potentially causing silent, irreversible damage to the optic nerve over time.
There is also a significant risk of physical injury during use. The recall notice specifically cites "broken cap spikes." A spike that is fractured or jagged can act like a sharp object. When you attempt to administer drops, your eye is in close proximity to the nozzle. If the plastic tip is unstable or broken, it could easily scratch the cornea (the clear front surface of the eye) or irritate the conjunctiva (the membrane lining the eyelids). Corneal abrasions are painful and can lead to secondary infections if not treated promptly. Furthermore, users have reported "undeliverable drops," which may lead to frustration and fumbling. In an effort to get the medication out, you might squeeze the bottle harder than intended or angle it incorrectly, increasing the likelihood of accidental contact between the broken plastic edge and your eye surface.
Additionally, ignoring the defect can compromise the sterility of the medication. Although the primary issue is mechanical, a compromised cap mechanism may not seal properly after use. This allows airborne contaminants, bacteria, or dust to enter the bottle more easily than with an intact container. Once the sterile environment inside the bottle is breached, the risk of introducing an infection into your eye increases significantly. Eye infections can escalate quickly and may require aggressive antibiotic treatment, adding unnecessary complexity and cost to your healthcare situation.
Finally, there is the consequence of delayed care. If you are struggling with a defective bottle, you might spend days trying to make it work or waiting for a replacement, during which time your condition goes untreated. In urgent cases, this delay can have serious implications. It is always safer to address the defect immediately rather than risk eye damage, infection, or uncontrolled disease progression due to a faulty delivery system.
Staying safe: broader tips
While this specific recall addresses a manufacturing defect in the packaging of a prescribed eye medication, the incident serves as a gentle reminder that safety often lives in the small details of how we handle our health products. Eye drops and ophthalmic solutions are delicate medical devices in their own right. Because they are applied directly to sensitive tissues, maintaining their sterility and ensuring the delivery mechanism functions correctly is critical. Here are some general best practices for keeping your eye care routine safe and effective.
First, always inspect the packaging before you first use a new prescription. When you pick up a new bottle of eye drops, take a moment to check that the seal is intact and the cap screws on securely. For multi-dose bottles, the tip that touches your eye must never be contaminated. A common mistake is letting the nozzle touch your eyelashes, fingers, or any surface. Even a brief touch can introduce bacteria into the bottle, turning a sterile solution into a potential source of infection. If you ever notice that the cap feels loose, the spike inside is broken, or the drops are not dispensing correctly, do not try to fix it yourself. Dispose of the product safely and contact your pharmacy for a replacement.
Honesty with your healthcare provider about any issues you encounter is also part of staying safe. If you notice strange behavior from a medication—such as inconsistent dosing, discoloration, or particles in the liquid—report it to your pharmacist or doctor immediately. They can help determine if it is an isolated issue or part of a larger pattern. Your feedback helps manufacturers and regulators identify problems before they affect others. You can also sign up for safety alerts from the FDA or your local health department to stay informed about recalls relevant to your medications.
Finally, consider how you store your eye drops. Most should be kept at room temperature, away from direct sunlight and moisture. Storing them in a humid bathroom cabinet can degrade the medication over time or damage the plastic components of the bottle. Keep them in a dry, cool place, and always tighten the cap firmly after each use to prevent evaporation and contamination. By treating your eye medications with care and respecting their packaging, you protect both your vision and your overall health.
- Check the seal and cap integrity before opening any new medication.
- Never let the tip of the bottle touch your eye or any surface.
- Store eye drops in a cool, dry place away from direct sunlight.
- Report any packaging defects or unusual product behavior to your pharmacist.